Understanding the RSV Threat

Respiratory Syncytial Virus (RSV) is a pervasive and often underestimated⁢ respiratory pathogen. While often causing ⁤mild, cold-like symptoms, RSV can lead to severe‍ illness, notably in infants, young children, and⁣ older adults. ⁣ Before the ⁤advent of these vaccines, RSV was responsible for an estimated 60,000-160,000 hospitalizations and 6,000-10,000 deaths annually among adults 65 years and older in the ⁤United States. Infants are also highly vulnerable, with nearly all children infected ⁣by age two.

The virus spreads through respiratory droplets produced ⁢when an infected person coughs or sneezes. Symptoms typically include a runny nose, decreased appetite, cough, sneezing, fever, and wheezing. In severe ⁣cases, RSV can lead to bronchiolitis (inflammation of the small airways in the lungs) and pneumonia.

The⁤ Landmark Vaccine Approvals

In ⁢May 2023, the Food and Drug ⁣Administration (FDA) approved the⁤ first RSV vaccines for⁢ both older adults and for the prevention of RSV in infants⁢ through maternal vaccination. This represents a monumental achievement in infectious disease prevention. Two vaccines were approved⁤ for adults 60 years and older: Arexvy (GSK) and Abrysvo (Pfizer). Abrysvo also received approval for maternal immunization to protect infants.

the vaccines utilize different technologies.⁢ Arexvy is a recombinant subunit vaccine⁣ containing a stabilized prefusion F protein, while Abrysvo employs a bivalent RSV prefusion F protein vaccine. ⁢Both aim to elicit an immune response that neutralizes the virus before ⁣it can cause ⁢severe illness.

Clinical Trial Results:⁢ Efficacy and Safety

Data published in the New⁣ England journal of Medicine ‍ on September 18,⁢ 2025, provides further ⁢insight into the real-world effectiveness of these vaccines. Studies demonstrated a significant reduction in RSV-associated LRTD among vaccinated adults. The RSV vaccine efficacy against severe disease in ⁤older adults ranged from 82.6% to 94.1% depending on the specific vaccine and study population.

Maternal ⁤vaccination with Abrysvo has shown promising results in protecting infants. Clinical trials indicated a considerable decrease in medically ⁣attended RSV-associated LRTD in infants born to⁤ vaccinated mothers, with efficacy‍ rates exceeding 80% for at least six months after birth.

Safety profiles were generally favorable. Common side effects included ⁣pain at the injection site, fatigue,⁢ muscle aches, and headache. Serious adverse events were rare and not consistently linked to the vaccines.